MMCAP Infuse Notice of RFP 34649

The MMCAP Infuse Request for Proposal (RFP) 34649 is a multi-state procurement seeking comprehensive drug and alcohol testing services and products for government agencies across 50 states, with 12,080 potential purchasing members. The solicitation covers both Department of Transportation (DOT) and non-DOT regulated testing programs, including pre-employment, random, post-accident, reasonable suspicion, return-to-duty, and confirmation testing scenarios. Vendors must demonstrate at least three years of experience providing testing services to government entities and be capable of serving a minimum of 10 states. The evaluation process will utilize a 70% technical proposal and 30% cost proposal scoring methodology, with proposals originally due on September 19, 2024, at 2:00 pm Central Time (though an addendum extended this to October 10, 2024). Required deliverables include comprehensive testing services across various testing types (breath alcohol, urine, hair, saliva/oral fluid), testing panels ranging from 5 to 14 panels, and additional services such as Medical Review Officer (MRO) services, regulatory policy review, and legal consultation.

The RFP includes specific set-aside designations and preference points for Minnesota-certified targeted group/economically disadvantaged businesses (12 points), veteran-owned businesses (12 points), and Minnesota resident vendors. Vendors will be required to pay a 3% administrative fee on all purchases and provide monthly sales and administrative fee reporting. While specific award values are not explicitly stated, the solicitation covers a broad range of testing products including testing kits, alcohol detection devices, harm reduction test strips, and impairment detection devices. The anticipated initial contract term is two years with potential extensions, and vendors must provide pricing that remains fixed for the first contract year with potential annual updates thereafter. The procurement is open to vendors who can demonstrate comprehensive testing capabilities, FDA-approved devices, CLIA waiver status for screening devices, and the ability to provide invoicing directly to member agencies while MMCAP Infuse collects administrative fees.